Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Percentage of patients with decreased C3 plasma concentration in the various subgroups of atypical hemolytic uremic syndrome

From: Atypical hemolytic uremic syndrome

  CFH mutation CFI mutation MCP mutation C3 mutation CFB mutation THBD mutation Anti -CFH Ab None
Decreased C3 concentration
(< 2SD)
(% patients)
30-50% 20-30% 0-27% 70-80% 100% 50% 40-60% up to 20%
  1. Normal C3 plasma concentration does not eliminate the presence of a mutation in the complement system or of anti- CFH antibodies. Conversely, decreased C3 level signs the presence of a complement abnormality.
  2. CFH: factor H; CFI: factor I; MCP: membrane cofactor protein; CFB: factor B; THBD: thrombomodulin; Ab, antibodies.